Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials
· The primary objective is to estimate the prevalence of use of complementary and alternative medicine (CAM) in patients with advanced malignancies who are seen in the Phase I clinic at MDACC.
· Examine the association between prevalence of CAM use and demographic and socioeconomic characteristics (age, gender, race, income, and education level), participation in a phase I clinical trial, disease characteristics (diagnosis), patients' perceptions about their prognosis, physicians' information and permission for patients' CAM use, decision-making, and types of CAM used by patients.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials|
- Prevalence of CAM use among patients enrolled in Phase I clinical trials (Questionnaire Response Rate) [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
|Study Start Date:||August 2009|
|Estimated Primary Completion Date:||August 2016 (Final data collection date for primary outcome measure)|
Phase I and CAM Survey
Complementary and alternative medicine (CAM) in patients with advanced malignancies currently treated on UT MDACC Phase I clinical trials.
Survey given at appointment time, then dropped in specified box anonymously.
This survey study is intended to estimate the prevalence of use of CAM in patients who are currently being treated in the Phase I Clinical Trials Program at UT MD Anderson Cancer Center. The survey includes questions about socioeconomic characteristics (age, gender, race, income, and education level), patients' diagnosis and patients' perceptions about their prognosis, physicians' information and permission for patients' use of CAM, patients' use of CAM (yes or no), decision-making (purpose of CAM use), resources and types of CAM.
Patients will be asked to drop the questionnaire into a box in a specified location after completion of the questionnaire. Accrual is expected to be 50-100 patients per month. This survey is expected to finish in 6 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00949390
|Contact: Aung Naing, MD||713-563-1930|
|United States, Texas|
|UT MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator: Aung Naing, MD|
|Principal Investigator:||Aung Naing, MD||UT MD Anderson Cancer Center|